JPH04202124A - Production of formulation controlling release of medicinal ingredient by spray-drying granulation method - Google Patents
Production of formulation controlling release of medicinal ingredient by spray-drying granulation methodInfo
- Publication number
- JPH04202124A JPH04202124A JP33636890A JP33636890A JPH04202124A JP H04202124 A JPH04202124 A JP H04202124A JP 33636890 A JP33636890 A JP 33636890A JP 33636890 A JP33636890 A JP 33636890A JP H04202124 A JPH04202124 A JP H04202124A
- Authority
- JP
- Japan
- Prior art keywords
- polymer coating
- medicinal ingredient
- granules
- spray
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001694 spray drying Methods 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 title abstract description 6
- 238000009472 formulation Methods 0.000 title abstract description 4
- 239000004615 ingredient Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title description 12
- 238000005469 granulation Methods 0.000 title description 3
- 230000003179 granulation Effects 0.000 title description 3
- 239000008187 granular material Substances 0.000 claims abstract description 25
- 239000011248 coating agent Substances 0.000 claims abstract description 21
- 229920000642 polymer Polymers 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 239000004014 plasticizer Substances 0.000 claims abstract description 10
- 239000002002 slurry Substances 0.000 claims abstract description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 6
- 229920002261 Corn starch Polymers 0.000 claims abstract description 4
- 239000008120 corn starch Substances 0.000 claims abstract description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims abstract description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 3
- 239000008101 lactose Substances 0.000 claims abstract description 3
- 239000000454 talc Substances 0.000 claims abstract description 3
- 229910052623 talc Inorganic materials 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 21
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 6
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 5
- 229940099112 cornstarch Drugs 0.000 claims description 3
- 238000000576 coating method Methods 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract description 4
- 238000007796 conventional method Methods 0.000 abstract description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 abstract description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 abstract 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 abstract 1
- -1 magnesium metasilicate aluminate Chemical class 0.000 abstract 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 14
- 238000010828 elution Methods 0.000 description 10
- 229960005489 paracetamol Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 4
- 239000008118 PEG 6000 Substances 0.000 description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、ｐＨ非依存性の薬物放出を特徴とするポリマ
ーコーティング顆粒の製法に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field] The present invention relates to a method for producing polymer-coated granules characterized by pH-independent drug release.
［従来の技術］
ポリマーコーティング技術を用いて、ｐＨ非依存性の剤
形を製造する方法としては、１）予め、薬物と賦形剤か
らなる錠剤式たは顆粒を製造し、２）次いで、パン−コ
ーテイング機を用いて、水、または有機溶媒に溶解し得
る徐放性ポリマーコーティング剤、例えばエチルセルロ
ース及びオイドラギットＲ３（Ｅｕｄ ｒａｇ ｉ ｔ
Ｒ８，レーム・ファーマ社製）等を錠剤式たは顆粒の表
面に噴霧し、マイクロカプセル化させる方法が知られて
いる。しかしながら、この方法は製造時に２工程を経な
ければならないため、製造コストが高くなる。[Prior Art] A method for manufacturing pH-independent dosage forms using polymer coating technology includes 1) manufacturing tablets or granules consisting of a drug and excipients in advance, 2) then: A pan-coating machine is used to coat sustained release polymeric coatings that can be dissolved in water or organic solvents, such as ethyl cellulose and Eudragit R3.
R8 (manufactured by Rehm Pharma) etc. is sprayed onto the surface of tablets or granules to form microcapsules. However, since this method requires two steps during manufacturing, the manufacturing cost is high.
また、ポリーマーコーティングの溶媒として有−′）−
機溶媒を使用した場合には、乾燥過程での爆発の危険性
及び使用有機溶媒による大気汚染、または得られた顆粒
中の残留溶媒等が問題となっている。In addition, when an organic solvent is used as a solvent for polymer coating, there are problems such as the risk of explosion during the drying process, air pollution from the organic solvent used, and residual solvent in the resulting granules. It becomes.
［発明が解決しようとする課題］
本発明は上記のような従来技術の問題点を解消し得る、
噴霧乾燥造粒法による薬物放出の制御された製剤の製造
法を提供することを目的とする。[Problems to be solved by the invention] The present invention can solve the problems of the prior art as described above.
An object of the present invention is to provide a method for producing a drug-release controlled preparation using a spray-drying granulation method.
［問題点を解決する手段］
本発明の目的とするｐＨ非依存性の薬物放出を特徴とす
る顆粒は、上述した従来の方法とは異なり、ポリマーコ
ーティング剤を溶かした溶液に可塑剤、賦形剤及び薬物
を加えて調製したスラリーを噴霧乾燥（スプレードライ
）することにより製造できる。[Means for Solving the Problems] Granules characterized by pH-independent drug release, which is the object of the present invention, differs from the above-mentioned conventional method by adding a plasticizer and an excipient to a solution containing a polymer coating agent. It can be manufactured by spray drying a slurry prepared by adding the agent and the drug.
本発明者らは、さらに、上記噴霧乾燥の過程でスラリー
中に溶解しているポリマーコーティング剤が顆粒の表面
に移動し、水分の蒸発後、固体として析出する際に、粒
子を被膜で覆うこと、また、得られた顆粒は、乾燥工程
で水分の蒸発により、粒子表面の被膜にわずかながら細
孔が生成し、結果としてｐＨ依存性の腸溶性ポリマーコ
ーティング剤、ＨＰＭＣＡＳを用いても、ｐＨ非依存性
の薬物放出を特徴とする顆粒を製造できることを見いだ
し本発明を完成させた。The present inventors further discovered that during the spray drying process, the polymer coating agent dissolved in the slurry migrates to the surface of the granules, and when the water evaporates and precipitates as a solid, the particles are covered with a film. In addition, in the obtained granules, a small amount of pores are generated in the coating on the particle surface due to the evaporation of water during the drying process, and as a result, even if a pH-dependent enteric polymer coating agent, HPMCAS, is used, the pH-independent granule is The present invention was completed by discovering that it is possible to produce granules characterized by dependent drug release.
上記、ポリマーコーティング剤としては、ヒドロキシプ
ロピルメチルセルロース（以下、ＨＰＭＣと省略する）
、及びヒドロキシプロピルメチルセルロースアセテート
サクシネート（以下、ＨＰＭＣＡＳと省略する）を挙げ
ることができる。As the polymer coating agent mentioned above, hydroxypropyl methyl cellulose (hereinafter abbreviated as HPMC)
, and hydroxypropyl methylcellulose acetate succinate (hereinafter abbreviated as HPMCAS).
ポリマーコーティング剤の溶解液としては、水及びアン
モニア水を用いることができる。例えばＨＰＭＣは水で
、ＨＰＭＣＡＳはアンモニア水を用いて溶液を調製する
ことができる。Water and aqueous ammonia can be used as the solution for the polymer coating agent. For example, a solution can be prepared using water for HPMC and aqueous ammonia for HPMCAS.
本発明において用いられるポリマーコーティング剤は処
方中の重址当たり、１０〜３０％の範囲であり、特に２
０〜２５％の範囲が好ましい。The polymer coating agent used in the present invention is in the range of 10 to 30% based on the weight of the formulation, especially 2
A range of 0 to 25% is preferred.
また、賦形剤としては、メタケイ酸アルミン酸マグネシ
ウム、タルク、コーンスターチ及びラクトースを挙げる
ことができる。本発明においては、これらの１種または
２種以上を組み合わせて用い一３＝
ることも可能である。Excipients may also include magnesium aluminate metasilicate, talc, cornstarch and lactose. In the present invention, it is also possible to use one or a combination of two or more of these.
また、可塑剤については、薬学上、通常使用されるもの
であればよく、特に限定されるものではない。Furthermore, the plasticizer is not particularly limited as long as it is commonly used pharmaceutically.
また、薬物としては、アセトアミノフェンを挙げること
ができるが、本発明の顆粒の製造法は特に用いる薬物に
より限定されるものではない。Further, as a drug, acetaminophen can be mentioned, but the method for producing granules of the present invention is not particularly limited by the drug used.
また、本発明の噴霧乾燥は、通常の方法で実施すること
ができる。即ち、乾燥機の入口／出口温度の粂件、また
は、液滴の微粒子化の方法としては、ノズル方式、ディ
スク方式及び２液体ノズル方式が知られているが、特に
限定されるものではない。Moreover, the spray drying of the present invention can be carried out by a conventional method. That is, the nozzle method, the disk method, and the two-liquid nozzle method are known as methods for controlling the inlet/outlet temperature of the dryer or for making droplets into fine particles, but these are not particularly limited.
才な、本発明の製造法で得られた顆粒の物性は、Ｘ線回
折、ＳＥＭ−ＢＥＴ及び流動性を測定することにより確
認できる９例えば上記噴霧乾燥の過程で、ポリマーコー
ティング剤が顆粒の表面に移動し一水分の蒸発後、固体
として析出する際に、粒子を被膜で覆うことは、走査電
子顕微鏡（、Ｊ ＳＭ−Ｔ２０’Ｏ１日本電子（株）社
製）を用い、ｌ００〜１，０００倍に拡大することによ
り、また、顆粒の結晶構造は、粉末Ｘ線回折装置（ガイ
ガーフレックスＲＡＤ−ＩＡ、（株）リガク社製）を用
いて確認することができる。The excellent physical properties of the granules obtained by the production method of the present invention can be confirmed by measuring X-ray diffraction, SEM-BET, and fluidity9. After evaporation of moisture, the particles were coated with a coating film using a scanning electron microscope (JSM-T20'O1 manufactured by JEOL Ltd.). The crystal structure of the granules can be confirmed using a powder X-ray diffraction apparatus (Geigerflex RAD-IA, manufactured by Rigaku Co., Ltd.) by magnifying the particles 1,000 times.
才た、上記顆粒からの薬物溶出の状況は、日周１及び、
２液を用い、一定時間毎の薬物の溶出旦を、例えば高速
液体クロマトグラフィを用いて、測定することにより確
認できる。The situation of drug elution from the above granules is as follows: diurnal cycle 1 and
This can be confirmed by using two liquids and measuring the elution time of the drug at regular intervals using, for example, high-performance liquid chromatography.
本発明の顆粒の製造法のさらに詳細な説明は、薬剤とし
て、アセトアミノフェン、可塑剤として、ポリエチレン
グリコール６０００ （以下、ＰＥＧ６０００と省略す
る）を用いた以下の実施例で述べる。A more detailed explanation of the method for producing the granules of the present invention will be given in the following example using acetaminophen as the drug and polyethylene glycol 6000 (hereinafter abbreviated as PEG6000) as the plasticizer.
以下余白
［実施例］
実施例１
アンモニアを含む水溶液２，０００ｍ１に攪拌下、ポリ
マーコーティング剤として、ＨＰＭＣＡＳ （２００ｇ
）と可塑剤としてＰＥＧ６０００ （４０ｇ）を溶解し
た後、アセトアミノフェン（３００ｇ）を加え、さらに
、メタケイ酸アルミン酸マグネシウム（２３０ｇ）とコ
ーンスターチ（２３０ｇ）を加え、殻終的に濃度が３０
％になるように水を加え、スラリーを調製した。The following margin [Example] Example 1 HPMCAS (200 g
) and PEG6000 (40g) as a plasticizer, acetaminophen (300g) was added, and then magnesium aluminate metasilicate (230g) and cornstarch (230g) were added to make the shell final concentration 30g.
% of water to prepare a slurry.
このスラリーを入口温度１５０〜１６０℃、出口温度７
５〜８５℃、ディスク回転数２０，０００ｒＩ）ｍ−′
ＦｆＬｉＬ１，０００〜２，０００ｍ Ｉ／ｈのスプレ
ードライ条件下で乾燥し、顆粒を製造した。This slurry is heated at an inlet temperature of 150 to 160℃ and an outlet temperature of 7.
5-85℃, disk rotation speed 20,000rI)m-'
FfLiL was dried under spray drying conditions of 1,000 to 2,000 m I/h to produce granules.
得られた顆粒と実施例１の配合Ｉで薬物、ポリマーコー
ティング剤、可塑剤と賦形剤を粉末混合したものは、い
ずれも薬物のピークの高さが同様であり、噴霧乾燥によ
る薬物の結晶構造の変化は見られなかった（第１図参照
）。即ち、顆粒からの薬物溶出は、被膜物質のみに依存
することがわかる。The obtained granules and the powder mixture of the drug, polymer coating agent, plasticizer, and excipient in Formulation I of Example 1 had similar drug peak heights, and the drug crystals by spray drying were No structural changes were observed (see Figure 1). That is, it can be seen that drug elution from the granules depends only on the coating material.
図１の粉末Ｘ線回折の各スペクトルは、（Ａ）はアセト
アミノフェン、（Ｂ）はＨＰＭＣＡＳとノイシリンとの
粉末混合物、（Ｃ）は本発明の顆粒を示す。In the powder X-ray diffraction spectra in FIG. 1, (A) shows acetaminophen, (B) shows a powder mixture of HPMCAS and neusilin, and (C) shows the granules of the present invention.
第１図 Ｘ線回折スペク１ヘル
このようにして得られた顆粒からの薬物の溶出試験は、
日周１．２液を用い、一定時間毎の薬物の溶出Ｉを、高
速液体クロマトグラフィを用いて測定する方法で行った
。Figure 1
Using diurnal 1.2 liquid, drug elution I was measured at fixed time intervals using high performance liquid chromatography.
溶出試験の結果を第２図に示す。The results of the dissolution test are shown in Figure 2.
第２図
・８局２遁
以上の結果から、顆粒からの薬物の溶出速度を、溶出率
８０％に達した時間（Ｔａｏ、ｔ）で比較すると日周１
液で５０分、２液で４０分とほとんど差がないことがわ
かる。Figure 2: From the results of 8 stations 2 and above, the elution rate of the drug from the granules is compared with the time (Tao, t) when the elution rate reaches 80%.
It can be seen that there is almost no difference between 50 minutes for the liquid and 40 minutes for the two liquids.
実施例２〜９
実施例２〜９では、アセトアミノフェン、ＰＥＧ６００
０の金蓋と、溶出試験の方法は実施例１と同様にして、
ポリマーコーティング剤及び賦形剤を、第１表に示す配
合割合で用いて製造した。Examples 2-9 In Examples 2-9, acetaminophen, PEG600
0 gold lid and the elution test method were the same as in Example 1.
The polymer coating agent and excipient were used in the proportions shown in Table 1.
その結果は第１表に示す。The results are shown in Table 1.
以下余白
−１１一
実施例１０
水（２，０００ｍ１）に攪拌下でポリマーコーティング
剤としてＨＰＭ、Ｃ（２００ｇ）と可塑剤としてＰＥＧ
６０００ （４０ｇ）を溶解させたのち。Margin below - 11 - Example 10 HPM as a polymer coating agent, C (200g) as a plasticizer and PEG as a plasticizer in water (2,000ml) under stirring.
After dissolving 6000 (40g).
アセトアミノフェン（３００ｇ）を添加し、次いで、メ
タケイ酸アルミン酸マグネシウム（４６０ｇ）を添加し
、最終的に濃度が３０％になるように水を加え、スラリ
ーを調製した。Acetaminophen (300 g) was added, then magnesium aluminate metasilicate (460 g) was added, and water was added to a final concentration of 30% to prepare a slurry.
スラリーの乾燥、及び薬物の溶出試験は実施例１と同様
にして行っ゛た。Drying of the slurry and drug elution test were conducted in the same manner as in Example 1.
顆粒からの薬物の溶出速度を、溶出率８０％に達した時
ｍ （’ｒ ｇｏ’−）で比較すると日周１液で３５分
、２液で２８分とほとんど差がないことがわかった。Comparing the elution rate of the drug from the granules in m ('r go'-) when the elution rate reached 80%, it was found that there was almost no difference between 35 minutes for the 1st solution and 28 minutes for the 2nd solution. .
溶出試験の結果は以下の第３図に示す。The results of the dissolution test are shown in Figure 3 below.
以下余白 第３図 実施例１１〜１５ 実施例１１〜１５では、アセトアミノフェン。Margin below Figure 3 Examples 11-15 In Examples 11-15, acetaminophen.
ＰＥＧ６０００の金蓋と、溶出試験の方法は実施例１と
同様にして、ポリマーコーティング剤及び賦形剤を、第
２表に示す配合割合で用いて顆粒を製造した。その結果
は第２表に示す。Granules were produced using a PEG6000 metal cap and the dissolution test method in the same manner as in Example 1, using polymer coating agents and excipients in the proportions shown in Table 2. The results are shown in Table 2.
［発明の効果］
本発明により、噴霧乾燥造粒法による薬物放出の制御さ
れた製剤を効率よく製造する方法を提供することができ
た。[Effects of the Invention] According to the present invention, it was possible to provide a method for efficiently producing a preparation with controlled drug release using a spray drying granulation method.
Claims (3)
、賦形剤及び薬物を加えて調製したスラリーを噴霧乾燥
（スプレードライ）して得られる、ｐＨ非依存性の薬物
放出を特徴とする顆粒の製造法。(1) Granules characterized by pH-independent drug release obtained by spray drying a slurry prepared by adding a plasticizer, an excipient, and a drug to a solution containing a polymer coating agent. Manufacturing method.
プロピルメチルセルロース（ＨＰＭＣ）、および／また
はヒドロキシプロピルメチルセルロースアセテートサク
シネート（ＨＰＭＣＡＳ）を用いることを特徴とする請
求項１記載の顆粒の製造法。(2) The method for producing granules according to claim 1, characterized in that hydroxypropylmethylcellulose (HPMC) and/or hydroxypropylmethylcellulose acetate succinate (HPMCAS) is used as the polymer coating agent.
ム、タルク、コーンスターチ及びラクトースからなる群
から選ばれた少なくとも１種または２種以上を含有する
事を特徴とする請求項１記載の顆粒の製造法。(3) The method for producing granules according to claim 1, characterized in that the excipient contains at least one or more selected from the group consisting of magnesium aluminate metasilicate, talc, cornstarch, and lactose. .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33636890A JPH04202124A (en) | 1990-11-29 | 1990-11-29 | Production of formulation controlling release of medicinal ingredient by spray-drying granulation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33636890A JPH04202124A (en) | 1990-11-29 | 1990-11-29 | Production of formulation controlling release of medicinal ingredient by spray-drying granulation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04202124A true JPH04202124A (en) | 1992-07-22 |
Family
ID=18298418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP33636890A Pending JPH04202124A (en) | 1990-11-29 | 1990-11-29 | Production of formulation controlling release of medicinal ingredient by spray-drying granulation method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04202124A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07309769A (en) * | 1994-05-17 | 1995-11-28 | Ind Technol Res Inst | Moistureproof herb granule preparation |
| JPH1171285A (en) * | 1997-06-30 | 1999-03-16 | Chugai Pharmaceut Co Ltd | Sucralfate-containing composition and its production |
| AT408068B (en) * | 1997-05-29 | 2001-08-27 | Lilly Co Eli | FLUOXETINPELLETS |
| JP2012214461A (en) * | 2011-03-30 | 2012-11-08 | Shin-Etsu Chemical Co Ltd | Coating composition, solid preparation coated with the same, and method for producing the solid preparation |
| JP2013006798A (en) * | 2011-06-24 | 2013-01-10 | Nitto Denko Corp | Method for manufacturing particulate preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61218516A (en) * | 1985-03-25 | 1986-09-29 | Ichimaru Fuarukosu Kk | Production of sustained release microcapsule |
| JPS6259207A (en) * | 1985-05-10 | 1987-03-14 | Ichimaru Fuarukosu Kk | Solid dispersion or microencapsulation of drug |
| JPH03193136A (en) * | 1989-10-03 | 1991-08-22 | Warner Lambert Co | Elongated globe-like microcapsule |
-
1990
- 1990-11-29 JP JP33636890A patent/JPH04202124A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61218516A (en) * | 1985-03-25 | 1986-09-29 | Ichimaru Fuarukosu Kk | Production of sustained release microcapsule |
| JPS6259207A (en) * | 1985-05-10 | 1987-03-14 | Ichimaru Fuarukosu Kk | Solid dispersion or microencapsulation of drug |
| JPH03193136A (en) * | 1989-10-03 | 1991-08-22 | Warner Lambert Co | Elongated globe-like microcapsule |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07309769A (en) * | 1994-05-17 | 1995-11-28 | Ind Technol Res Inst | Moistureproof herb granule preparation |
| AT408068B (en) * | 1997-05-29 | 2001-08-27 | Lilly Co Eli | FLUOXETINPELLETS |
| JPH1171285A (en) * | 1997-06-30 | 1999-03-16 | Chugai Pharmaceut Co Ltd | Sucralfate-containing composition and its production |
| JP2012214461A (en) * | 2011-03-30 | 2012-11-08 | Shin-Etsu Chemical Co Ltd | Coating composition, solid preparation coated with the same, and method for producing the solid preparation |
| JP2013006798A (en) * | 2011-06-24 | 2013-01-10 | Nitto Denko Corp | Method for manufacturing particulate preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3707831B2 (en) | Duloxetine enteric pellet | |
| FI103475B (en) | Process for the preparation of a controlled release preparation | |
| US5384130A (en) | Spherical seed cores, spherical granules and process for production thereof | |
| EP0452862B1 (en) | Spherical seed cores, spherical granules and process for production thereof | |
| US6699506B1 (en) | Pharmaceutical composition with extended release of Milnacipran | |
| WO1998010756A1 (en) | Sustained-release preparation utilizing thermal change and process for the production thereof | |
| AU2166492A (en) | Process for preparing drug substances in beadlet form | |
| KR20080074083A (en) | Solid formulation for medicine comprising sparingly soluble drug and process for preparing the same | |
| JP2004517064A (en) | Microgranules based on active ingredients and process for their production | |
| TWI243063B (en) | Orally administrable nifedipine pellet and process for the preparation thereof | |
| JPH04202124A (en) | Production of formulation controlling release of medicinal ingredient by spray-drying granulation method | |
| JP3471977B2 (en) | Enteric preparations coated with solvent-free enteric coatings using liquid plasticizers | |
| JP2915653B2 (en) | Masked granules | |
| JP3803446B2 (en) | Method for producing solid preparation controlled by insulation resistance meter | |
| JP2001192344A (en) | Film coating agent and oral solid preparation | |
| JPH04342523A (en) | Production of wax coated preparation | |
| JPS615010A (en) | Sustained release preparation of hydrogenated ergot-alkaloid and its preparation | |
| JPH08333238A (en) | Enteric coated preparation coated by solventless enteric coating agent using liquid wax | |
| JPH05507937A (en) | Method of manufacturing gelatin coated drug | |
| JPS6141325B2 (en) | ||
| JPS635030A (en) | Production of coated drug | |
| JPH0768121B2 (en) | Solid drug coating method | |
| JP3417772B2 (en) | Solvent-free coated solid preparation and subsequent treatment method | |
| JPH057366B2 (en) | ||
| JPS61218516A (en) | Production of sustained release microcapsule |